Revenue
No reported data
Adicet Bio, Inc. (ACET)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | $99.1M | $99.3M | $106.0M | $71.2M | $48.9M | $34.3M | $23.7M | $14.7M | $16.8M |
| Operating expenses | $122.1M | $127.6M | $152.0M | $97.5M | $71.2M | $57.1M | $32.4M | $23.1M | $18.9M |
| Operating income | −$122.1M | −$127.6M | −$152.0M | −$72.6M | −$61.4M | −$39.2M | −$31.4M | −$15.0M | −$18.9M |
| EBITDAderived | −$115.7M | −$121.1M | −$145.9M | −$70.0M | −$59.9M | −$38.0M | −$30.1M | −$13.7M | −$18.9M |
| Net income | −$116.8M | −$117.1M | −$142.7M | −$69.8M | −$62.0M | −$36.7M | −$28.1M | −$9.3M | −$33.8M |
| Basic EPSper diluted share | -$16.95 | -$21.33 | -$3.31 | -$1.70 | -$2.00 | -$5.01 | -$13.15 | -$4.78 | -$8.42 |
| Diluted EPSper diluted share | -$16.95 | -$21.33 | -$3.31 | -$1.70 | -$2.00 | -$5.01 | -$13.15 | -$4.78 | -$8.42 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 40.4K | $6.52 | $263.5K | 0 |
| Apr 8, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 32.5K | $6.29 | $204.6K | 0 |
| Apr 7, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 2.4K | $6.38 | $15.3K | 32.5K |
| Apr 7, 2026Form 4 | OrbiMed Advisors Israel II Ltd +7TenPercentOwner | SellCommon Stock · indirect | 29.3K | $6.53 | $191.5K | 34.9K |
| Feb 20, 2026Form 4 | RA Capital Healthcare Fund LP +3TenPercentOwner | BuyCommon Stock · indirect | 74.8K | $7.27 | $543.4K | 1.18M |